Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Patients with AML who achieve long term complete remission do not have a normal life expectancy when compared to the general population. Analysis of 3,012 patients enrolled on 9 consecutive ECOG-ACRIN trials
    Meeting Abstract

    Ganzel, C.; Roopcharan, K.; Sun, Z.; Rowe, J. M.; Fernandez, H. F.; Paietta, E. M.; Luger, S. M.; Lazarus, H. M.; Cripe, L. D.; Douer, D.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical and genomic characterization of secondary acute myeloid leukemia with mixed phenotype
    Meeting Abstract

    Galera, P.; Chan, A.; Derkach, A.; Liu, Y.; Baik, J.; Famulare, C.; Sigler, A.; Arcila, M. E.; Mata, D. A.; Dogan, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • DNMT3A mutations in the hematopoietic system promote colitis-associated colon cancer: A model of clonal hematopoiesis in solid tumors
    Meeting Abstract

    Feng, Y.; Newsome, R.; Robinson, T.; Bowman, R. L.; Zuniga, A.; Hall, K.; Bernsten, C.; Shabashvili, D.; Krajcik, K.; Gunaratne, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Entospletinib (ENTO) and decitabine (DEC) combination therapy in older newly diagnosed (ND) acute myeloid leukemia (AML) patients with mutant TP53 or complex karyotype is associated with poor response and survival: A phase 2 sub-study of the Beat AML Master Trial
    Meeting Abstract

    Duong, V. H.; Ruppert, A. S.; Mims, A. S.; Borate, U.; Stein, E. M.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W. G.; Arellano, M. L.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) during treatment with enasidenib (ENA) plus azacitidine (AZA) in patients with newly diagnosed mutant IDH2 (m IDH2) acute myeloid leukemia (AML) not eligible for intensive chemotherapy (IC)
    Meeting Abstract

    DiNardo, C. D.; Dohner, H.; Zeidan, A. M.; Schuh, A. C.; Vyas, P.; Stein, E. M.; Wei, A. H.; de Botton, S.; Chen, C.; Lord-Bessen, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical predictors of outcome in adult patients with acute leukemias and myelodysplastic syndrome and COVID-19 Infection: Report from the American Society of Hematology Research Collaborative (ASH RC) data hub
    Meeting Abstract

    Desai, P.; Goldberg, A. D.; Anderson, K. C.; Narendra, V.; Neuberg, D. S.; Radhakrishnan, V.; Redd, R. A.; Roboz, G. J.; Sehn, L. H.; Sekeres, M. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Single cell ATAC lineage deconvolution reveals overlapping subclones in epigenetically distinct AML samples
    Meeting Abstract

    Dilip, D.; Koche, R.; Menghrajani, K.; Melnick, A.; Elemento, O.; Levine, R. L.; Glass, J. L.
    Blood (2021)

    Fulltext@MSK | Save
  • MAJIC: A phase 3 prospective, multicenter, randomized, open-label trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma
    Meeting Abstract

    Davids, M. S.; Mato, A. R.; Hum, J.; Wargo, S.; Emeribe, U.; Shahkarami, M.; Sokolowski, K.; Biondo, J. M. L.; Abhyankar, S.; Hermann, R.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Post hoc analysis of responses to ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) by baseline BCR-ABL1 level and baseline mutation status in the OPTIC trial
    Meeting Abstract

    Deininger, M. W.; Apperley, J. F.; Arthur, C. K.; Chuah, C.; Hochhaus, A.; De Lavallade, H.; Lipton, J. H.; Lomaia, E.; McCloskey, J. K.; Maness, L. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • An update of safety and efficacy results from phase 1 dose-escalation and expansion study of vodobatinib, a novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI), in patients with chronic myeloid leukemia (CML) and philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) failing prior TKI therapies
    Meeting Abstract

    Cortes, J. E.; Saikia, T.; Kim, D. W.; Alvarado, Y.; Nicolini, F. E.; Rathnam, K.; Khattry, N.; Apperley, J. F.; Deininger, M. W.; de Lavallade, H.; more...
    Blood (2021)

    Fulltext@MSK | Save